Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
dRx Capital is a venture capital firm founded in 2015 and based in Basel, Switzerland. It operates as a joint venture between Novartis and Qualcomm Ventures, focusing on investments in the healthcare sector, particularly digital health companies. The firm has established itself as a key player in the digital health space, targeting early to growth-stage investments that leverage technology to improve healthcare delivery and patient outcomes.
Currently, dRx Capital manages a fund size of $100 million and has invested in a portfolio of 20 companies. The firm has received recognition for its innovative approach, winning the Global Corporate Venturing New Entrant of the Year and Fund of the Year awards shortly after its inception. Its strategic location in Basel, near Novartis' headquarters, allows for close collaboration with its corporate partners, enhancing its investment capabilities.
dRx Capital targets early to growth-stage companies within the digital health sector, with a specific emphasis on those utilizing artificial intelligence, big data, and technology to optimize patient care and healthcare delivery. The firm invests across a range of stages, from pre-seed to growth equity, and operates primarily in North America and Europe. This geographic focus allows dRx Capital to tap into diverse healthcare markets and innovative startups.
The investment thesis centers on the convergence of information technology and healthcare, seeking companies that can integrate into the corporate ecosystems of Novartis and Qualcomm. dRx Capital looks for founders who demonstrate a strong vision and the ability to execute on innovative solutions that address critical healthcare challenges. The firm prefers deal structures that allow for strategic partnerships, leveraging the resources and expertise of its corporate backers.
dRx Capital's portfolio consists of 20 companies, showcasing a diverse range of digital health solutions. Notable portfolio companies include:
Dr. Thomas G. Schmid: Managing Partner at dRx Capital, Dr. Schmid has extensive experience in venture capital and healthcare investments. He has a background in strategic management and has led numerous successful investments in the digital health sector.
Dr. Michael H. Schmitt: Partner at dRx Capital, Dr. Schmitt brings expertise in healthcare technology and innovation. His previous roles include significant positions in healthcare startups and venture capital firms, focusing on digital health solutions.
Dr. Andreas M. Schmid: Partner at dRx Capital, Dr. Andreas Schmid has a strong background in healthcare and technology investments. He has been involved in various successful ventures in the digital health space, contributing to the firm's strategic direction.
To pitch to dRx Capital, startups should visit their website at drxcapital.com. It is recommended to include a comprehensive business plan in the pitch deck, detailing the startup's technology, market strategy, and potential impact on healthcare delivery. dRx Capital appreciates well-structured pitches that highlight the integration of the startup's solution into existing healthcare frameworks.
Response times may vary, but founders should expect a thorough review process given the firm's focus on strategic fit and potential for impact. Warm introductions are preferred, as they can facilitate a more favorable review process.
In 2023, dRx Capital faced a notable portfolio loss with the bankruptcy of Pear Therapeutics, a pioneer in digital therapeutics. This event highlights the challenges within the digital health sector.
In January 2015, dRx Capital co-invested $12 million in GoBalto, a medical testing software company, marking one of its early deals in the digital health space. The firm continues to actively deploy capital across its portfolio, focusing on digital health convergence plays.
What are dRx Capital's investment criteria?
dRx Capital invests in early to growth-stage companies within the digital health sector, focusing on those that leverage technology to enhance healthcare delivery and patient outcomes. The firm looks for innovative solutions that address critical healthcare challenges.
How can startups apply or pitch to dRx Capital?
What makes dRx Capital different from other venture capital firms?
dRx Capital's unique structure as a joint venture between Novartis and Qualcomm Ventures provides access to extensive resources, clinical networks, and regulatory expertise. This enables portfolio companies to scale effectively and integrate into existing healthcare systems.
What is the geographic scope of dRx Capital's investments?
The firm primarily invests in North America and Europe, allowing it to tap into diverse healthcare markets and innovative startups across these regions.
What is the typical check size for investments made by dRx Capital?
dRx Capital invests across a range of stages, from pre-seed to growth equity, with check sizes varying based on the stage and specific needs of the portfolio company.
What kind of post-investment involvement does dRx Capital have?
dRx Capital actively supports its portfolio companies through access to Novartis and Qualcomm's resources, including clinical networks and regulatory expertise, which can significantly enhance the growth trajectory of the startups.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.